A clinical-stage and cell-&-gene-therapy hub. Compare MHRA-regulated UK CDMOs across biologics, advanced therapies, and drug product — by capability and site.
1 company listed
The United Kingdom has a distinctive CDMO profile weighted toward clinical-stage manufacturing, biologics, and cell & gene therapy — reflecting its dense academic-biotech ecosystem around the Golden Triangle of Cambridge, Oxford, and London, plus advanced-therapy clusters in Stevenage and the north.
Post-Brexit, UK manufacturing is regulated by the MHRA, which has positioned itself as an agile regulator with recognition routes that ease parallel UK, EU, and US programs. For early-phase and advanced-therapy work, the UK offers a deep pool of specialist capacity and English-language regulatory alignment.
The UK is a particularly strong fit for clinical trial material supply and cell-&-gene-therapy manufacturing, where its concentration of specialist CDMOs and proximity to leading academic centers shortens the path from research to GMP production.
How this list is built: companies appear here when they have a manufacturing site in United Kingdom in our facilities dataset and pass the marketplace eligibility gate (pharmaceutical contract manufacturers only — CROs, equipment suppliers, and other non-manufacturers are excluded). Read the full methodology for the eligibility gates and how our ranked lists are computed.
Our AI Matchmaker analyzes your project requirements and matches you with qualified United Kingdom manufacturing partners. Free for buyers.